Art

J-GLOBAL ID：201702287900547891   Reference number：17A1363209

Contrasting effects of cyclophosphamide on anti-CTL-associated protein 4 blockade therapy in two mouse tumor models

2種のマウス腫瘍モデルにおける抗CTL関連蛋白質4阻害療法に及ぼすシクロホスファミドの対照的な効果

Author (7)： Iida Yuichi (Department of Immunology, Faculty of Medicine, Shimane University, Shimane, Japan) ,  Harashima Nanae (Department of Immunology, Faculty of Medicine, Shimane University, Shimane, Japan) ,  Harashima Nanae (Laboratory of Biometabolic Chemistry, Faculty of Medicine, School of Health Sciences, University of Ryukyus, Okinawa, Japan) ,  Motoshima Takanobu (Department of Urology, Graduate School of Medical Science, Kumamoto University, Kumamoto, Japan) ,  Komohara Yoshihiro (Department of Cell Pathology, Graduate School of Medical Science, Kumamoto University, Kumamoto, Japan) ,  Eto Masatoshi (Department of Urology, Graduate School of Medical Science, Kyushu University, Fukuoka, Japan) ,  Harada Mamoru (Department of Immunology, Faculty of Medicine, Shimane University, Shimane, Japan)
Material： Cancer Science (Web)  (Cancer Sci (Web))
Volume： 108  Issue： 10  Page： 1974-1984  Publication year： 2017 
JST Material Number： U0505A  ISSN： 1349-7006  Document type： Article
Article type： 原著論文  Country of issue： United States (USA)  Language： ENGLISH (EN)

Thesaurus term： mouse(animal) ,...
Semi thesaurus term： CD8(+) T cell ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=17A1363209&from=J-GLOBAL&jstjournalNo=U0505A") }}

Author keywords (5)： Anti-CTLA-4 therapy ,  CCL2 ,  cyclophosphamide ,  IL-6 ,  MDSC

JST classification (4)： Tumors(=neoplasms)of digestive system  (GH04000D) ,  Experimental treatment for tumors  (GE02040Y) ,  Basic research of antitumor(=antineoplastic)drugs  (GW16010A) ,  Urogenital tumors(=neoplasms)  (GM04000S)

Substance index (1)： Cyclophosphamid

Reference (46)：

• Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer 2016; 16: 275-87.
• Ott PA, Hodi FS, Robert C. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res 2013; 19: 5300-9.
• Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 2015; 16: 205-14.
• Pfirschke C, Engblom C, Rickelt S et al. Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy. Immunity 2016; 44: 343-54.
• Michot JM, Bigenwald C, Champiat S et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 2016; 54: 139-48.

Terms in the title (9)： マウス ,  腫瘍 ,  モデル ,  CTL ,  蛋白質 ,  阻害 ,  療法 ,  シクロホスファミド ,  対照